Recent clinical studies and management guidelines for the treatment of the organic acidopathies methylmalonic acidemia (MMA) and propionic acidemia address the scope of interventions to maximize health and quality of life. Unfortunately, these disorders continue to cause significant morbidity and mortality due to acute and chronic systemic and end-organ injury.
INTRODUCTION
Methylmalonic acidemia (MMA) and propionic acidemia are rare, autosomal recessive, multisystemic inborn errors of branched-chain amino acid metabolism, which cause significant morbidity and mortality in infancy and childhood and, for survivors, significant debilitating end-organ damage into adulthood. MMA and propionic acidemia, as organic acidopathies, result in defective mitochondrial metabolism of CoA-activated carboxylic acids, which are largely derived from the metabolism of branched-chain amino acids, odd-chain fatty acids, and cholesterol. Clinical features of organic acidopathies may occur due to accumulation of toxic metabolites, altered mitochondrial energy metabolism, carnitine depletion, and CoA sequestration. Acute illness may be associated with metabolic acidosis, acute alterations of consciousness or encephalopathy, anorexia, and nausea and vomiting [1, 2] . Chronic complications include poor growth, movement disorders, progressive spastic quadraparesis, epilepsy, cardiac dysfunction (propionic acidemia >MMA), progressive renal disease (MMA), osteopenia/osteoporosis, vision loss (MMA> propionic acidemia), and functional immunodeficiency [1,3-17,18 & ,19-31,32 & , [33] [34] [35] . Recent investigation into the pathophysiology of the end-organ effects seen in patients with organic acidopathies has improved screening for diseaserelated complications, and recent treatment Propionic acidemia and MMA classically present in a term neonate within the first 3 days of life, who feeds poorly, is pancytopenic, becomes progressively encephalopathic, and ultimately progresses to coma and death without prompt identification and management [22, [37] [38] [39] [40] [41] [42] [43] [44] . The differential diagnosis in this age group includes sepsis, hypoxicischemic encephalopathy, drug intoxication (from maternal exposure before and/or during delivery), and other inborn errors of metabolism (IEM). Sick neonates who appear septic or encephalopathic with an anion gap metabolic acidosis, ketoacidosis, lactic acidosis, hyperammonemia, and/or hypoglycemia should be stabilized expectantly with reversal of catabolism using dextrose-containing fluids with a glucose infusion rate of 6-8 mg/kg/min, with intralipids at 2-3 g/kg/day, whereas removing all source of protein from the infant. Workup for intoxication-type IEM should occur immediately upon clinical indication and include blood gas (noncapillary), comprehensive metabolic panel, complete blood count, blood culture, urinalysis (specifically for urine ketones, which should be negative in a healthy newborn without and IEM), lactate, ammonia, urine organic acids, plasma amino acids, and an acylcarnitine profile [45] .
Once the infant is acutely stabilized and diagnosed, lifelong aggressive management by metabolic physicians remains essential. Despite management based on best practices, including dietary protein restriction, carnitine supplementation, and the use of drugs to modulate ammonia, these patients frequently experience acute metabolic decompensation during acute illness or other stressors such as surgical or interventional procedures [1, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . In older patients with the classical organic acidopathies, acute decompensation events continue frequently due to viral illness or surgical procedures. Frequently, these patients will have significant complications due to their disease, which are discussed below.
Patients with milder variants of isolated MMA [mut À , or the cobalamin disorders cobalamin A (cblA) or B (cblB), which result in deficiency of the adenosylcobalamin cofactor for MUT] or propionic acidemia may not present until later in infancy, childhood, or adolescence. Although the definition of early versus late onset remains controversial within the organic acidopathies, Heringer et al. [58 & ] classify late-onset disease as any patient in whom the first clinical symptoms occur outside of the neonatal (first 30 days of life) period, whereas some patients may not present until much later in life. In patients who were not diagnosed by expanded newborn metabolic screening (NMS), Heringer et al. [58 & ] report that for MMA and propionic acidemia, the median age at onset of clinical symptoms was 6-8 days in the early-onset group, whereas in the late-onset group, the median age at diagnosis was 210-348 days. Approximately half of the non-NMS MMA and propionic acidemia cohort were classified as late-onset, but most of these diagnoses occurred during infancy [58 & ]. In MMA, these childhood and adolescent-onset patients may present with chronic renal failure, and evaluation for MMA should occur in all patients who present with progressive proximal tubular renal dysfunction [59] [60] [61] [62] [63] . Late-stage presentation of propionic acidemia may include seemingly isolated cardiomyopathy, whereas patients with propionic acidemia and MMA may present with progressive spastic quadraparesis, progressive movement disorder, or vision loss [6,7,14,32 & ,33,35,57,64-70] . Some patients who self-restrict protein due to limited protein tolerance may present later in life with metabolic decompensation or metabolic stroke following a surgical or interventional procedure in which fasting for several hours is required. Additional complications of late-onset MMA and propionic acidemia are similar to those with classical disease and are discussed below.
DIAGNOSIS
Diagnosis typically occurs during an initial decompensation event in the neonatal period, which may resemble neonatal sepsis and present with poor
KEY POINTS
Diagnostic and management guidelines for propionic acidemia and MMA are emerging and may improve long-term care.
Prospective, controlled studies are needed to support the use of medical foods and their formulations to limit iatrogenic morbidity in propionic acidemia and MMA.
The pathophysiology of metabolic brain injury in the organic acidopathies requires further elucidation to permit future drug targeting for neuroprotection and recovery.
Orthotopic liver transplantation improves metabolic stability in patients with organic acidopathies and will likely change the natural history of these disorders, but is not curative.
feeding, vomiting, lethargy, and progression to coma and death without prompt and effective therapy. Diagnosis is based on clinical presentation and laboratory analysis, metabolic acidosis, ketoacidosis, lactic acidosis, hyperammonemia, hypoglycemia, pancytopenia, and elevated C3 acylcarnitines and organic acids in the urine. Metabolites elevated in propionic acidemia include elevated plasma propionylcarnitine, glycine, alanine, and elevated urinary 3-OH-propionate and methylcitrate [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] . In MMA, elevations of plasma propionylcarnitine, glycine, and alanine coupled with elevation of urinary methylmalonic, 3-OH-propionic, and methylcitric acids provide the diagnosis [71] [72] [73] [74] [75] [76] [77] [85] [86] [87] .
Some infants, however, are detected on the basis of NMS prior to a decompensation event. A recent study of organic acidemia outcomes using compiled data from the European registry and network for intoxication type metabolic diseases demonstrates that for infants diagnosed with organic acidopathies on newborn screening, 52% with cobalamin nonresponsive MMA, 67% with cobalamin responsive MMA, and 49% with propionic acidemia were asymptomatic at 8 days of life [58 & ]. Organic acidopathy patients detected by expanded NMS are somewhat more likely to have normal development of motor milestones and less likely to have a movement disorder, although movement disorders and metabolic brain injury may occur at any age, and the median age of patients in this study was under 10 years [58 & ]. Furthermore, other neurological and neurocognitive outcomes were not explored, and thus, in spite of earlier detection, these patients are likely to develop some degree of neurological sequela of disease, and other end-organ sequelae have not been analyzed in this cohort.
Defects in other genes within the propionate catabolism pathway or mitochondrial disorders may also result in excretion of methylmalonic acid in the urine [88, 89] . These disorders are rarer than classical isolated MMA, often manifest other biochemically diagnostic markers in urine or plasma to suggest the diagnosis, and will not be addressed further in this review.
BIOCHEMICAL PERTURBATIONS IN PROPIONIC ACIDEMIA AND METHYLMALONIC ACIDEMIA
Mutations in the PCCA and PCCB genes cause propionic acidemia by generating defective or absent propionyl-CoA carboxylase (PCC), which is biochemically upstream of MUT . Isolated MMA is caused by mutations in the MUT gene encoding methylmalonyl-CoA mutase (mut) or the genes encoding the enzymes responsible for the generation of 5-deoxyadenosylcobalamin (AdoCbl) cofactor of Mut (MMAA and MMAB) ( Fig. 1 ) [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] . The subtypes of MMA are based on complementation subclasses and include mut, cblA, and cblB based on the enzymatic cause of the condition [148] . Mut deficiency may be further divided into subclasses based on the degree of enzymatic activity of the mutase enzyme, designated mut 0 , for enzymes with null activity, and mut À for enzymes with reduced or minimal activity [140] . Other causes of isolated MMA include much rarer deficiencies in other enzymes within the propionate catabolism pathway or in other components of mitochondrial function.
With normal enzymatic function, propiogenic precursors are converted sequentially from propionyl-CoA to methylmalonyl-CoA to succinyl-CoA, which is subsequently metabolized within the krebs cycle [130, 131, [149] [150] [151] . This complex role of PCC and MUT within mitochondrial energy metabolism mirrors the biochemical and clinical findings associated with organic acidopathy disease [152] [153] [154] [155] [156] [157] [158] . Approximately two-thirds of normal propiogenic load is generated from dietary intake and muscle turnover, whereas around one-third naturally originates from gut bacterial sources [159, 160] . During decompensation, acidosis in these patients occurs due to accumulation of organic acids and ketoacids, whereas lactic acidosis also occurs, particularly in severe decompensation or with severe secondary mitochondrial dysfunction [60, [161] [162] [163] [164] [165] . Accumulation of propionyl-CoA, and to some extent methylmalonyl-CoA, results in secondary inhibition of N-acetylglutamate synthase, causing secondary hyperammonemia in these patients [166] [167] [168] [169] . Generation of propionylcarnitine moieties may result in cardiac arrhythmias and cardiomyopathy due to secondary carnitine deficiency [29, 170] .
COMPLICATIONS AND MANAGEMENT OF METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA
Because normal mitochondrial function requires sufficient energy production through the citric acid cycle and oxidative phosphorylation, MMA and propionic acidemia result in multisystemic chronic disease, particularly in the highly energetic organs such as brain, heart, kidney, and eye. End-organ injury occurs due to both primary toxicity of both the accumulating primary and secondary metabolites and deficiency of succinyl-CoA resulting in Kreb cycle and oxidative phosphorylation dysfunction. Periods of acute illness frequently chronically worsen the patient's basal condition due to increased energetic dysfunction.
DIETARY MANAGEMENT
In the well state, organic acidopathy patients are typically maintained on a protein-limited diet, or if enteral gastric feedings are required, combinations of standard, age-appropriate enteral formulas with formulas specially designed for organic acidopathy patients may be employed. Although protein restriction is more aggressive in patients with other IEM, in organic acidopathies dietary protein intake should target the recommended daily allowance for protein (0.8 g protein/kg body weight), unless differences based on the individual patient response require lower or higher concentrations. Patients with spasticity or severe choreoathetosis may require additional protein nutrition for their increased energetic demand, and other patients with brittle, difficult-to-manage disease may require less whole protein and, based on clinician preference, addition of medical foods or formulas [12, 53, [171] [172] [173] [174] [175] [176] [177] [178] . The primary dietary goal in organic acidopathy patients should remain the prevention of catabolism and allow normal growth, without causing obesity. Thus, providing sufficient protein, preferably from natural protein sources with as little amino aciddeficient protein from medical foods as possible, is preferred. Recently, dietary analysis of a large cohort of patients has revealed that patients with MMA typically tolerate the recommended daily allowance of protein. However, many of these patients were receiving a large proportion of protein from propiogenic-deficient sources and were also noted to have poor growth in height and weight, elevated leucine levels, and low levels of isoleucine and valine, often requiring specific amino acid supplementation [179 & ]. Prior patients on such diets developed severe amino acid deficiencies [175, 177] . Thus, the use of medical foods deficient in propiogenic precursors appears to result in branched-chain amino acid deficiencies and may worsen outcomes. Therefore, coordination with a metabolic dietician is strongly recommended to ensure that nutritional and amino acid deficiencies are prevented, and future prospective studies on the safety and efficacy of medical foods for organic acidopathies should be undertaken to ensure that iatrogenic secondary effects are prevented in this already vulnerable population.
MEDICAL MANAGEMENT
Patients with propionic acidemia and MMA require carnitine supplementation to prevent secondary carnitine deficiency (L-carnitine, enterally administered at 50-100 mg/kg/day), and those patients with B12 responsive MMA, usually cblA disease, should receive daily injections of hydroxocobalamin (1 mg, intramuscularly every day) [12, 56, 143, 144, 180, 181] . Some patients are treated with cycles of enteral antibiotics (metronidazole) to reduce the burden of propiogenic gut flora [36 && ,160,172,182] . Some brittle patients with chronic hyperammonemia may be treated orally with sodium benzoate or sodium phenylbutyrate (Buphenyl; Horizon Pharma USA, Inc., Lake Forest, Illinois, USA) at 10 g/m 2 /day, with careful monitoring of amino acid levels and electrolytes [12,36 && ]. This is not a standardized practice, but may be instituted by a metabolic physician based on professional experience and provider preference.
ACUTE METABOLIC DECOMPENSATION
Patients with organic acidopathies may become very ill from otherwise mild viral illnesses, and other events that cause physical or emotional stress may trigger catabolism, including surgical procedures, labor and childbirth, and abrupt changes in nutritional status. Aggressive acute management of intercurrent illness and mitigation of other stressors must be undertaken to limit the degree of decompensation and sequelae from these events. Limited reports indicate that patients with propionic acidemia and MMA may not maintain sufficient humoral immune response to combat viral infection [183,184 & ]. Reversal of catabolism, promotion of anabolism, and identification and treatment of the underlying precipitating cause are paramount to management of the acute decompensation.
With intercurrent illness, propionic acidemia and MMA patients typically present with nausea and vomiting, worsening anorexia, and encephalopathy, with laboratory studies demonstrating metabolic acidosis, ketonuria, hyperammonemia, pancytopenia, and electrolyte disturbances [1, 22, 45, 85] . These decompensation events typically present with decreased oral intake or enteral feeding intolerance, vomiting, and altered mental status or lethargy. Without aggressive reversal of catabolism with intravenous dextrose-containing fluids (typically 10-12.5% dextrose in isotonic saline with appropriate electrolyte additives at 150% of maintenance, unless renal function demands different electrolyte composition or volume), patients with organic acidopathies may die or suffer severe metabolic brain injury [22,36 && ,45]. Some providers choose to employ intralipid in addition to dextrose fluids for additional caloric support [36 && ,45] . In addition to reversal of catabolism, more aggressive metabolic therapies are employed during decompensation, including ammonia scavenging with sodium phenylacetatesodium benzoate (Ammonul, Ucyclyd Pharma, Inc., Scottsdale, Arizona, USA; intravenous preferably via central line, variable dosing based on age/weight) or disinhibition of urea cycle function by N-carbamylglutamate (Carbaglu, Recordati Rare Diseases Inc., Lebanon, New Jersey, USA; oral, 100 mg/kg bolus followed by 25-62 mg/kg every 6 h, currently under investigational status with the United States Food and Drug Administration) [36 && ,45,185-188] . The ammonia scavengers allow conjugation of amino acids to the scavenger compounds to bypass the urea cycle and permit excretion [39, 158, 189, 190] . Inhibition of carbamylphosphate synthetase 1 (CPS1), a urea cycle enzyme, by accumulating metabolites in organic acidopathies causes secondary hyperammonemia in these disorders [166] . N-carbamylglutamate, an N-acetylglutamate analog, allosterically activates CPS1 and inhibits the secondary effects of the propionate metabolites on CPS1 [36 && , 45, 188,191 & ,192-194] . Once catabolism has been reversed and acidosis corrected, complete nutrition should be reinitiated as soon as possible, preferably via the enteral route. Once the precipitating source is identified and treated or managed, the patient may be transitioned back to standard diet.
CHRONIC MANAGEMENT AND SCREENING RECOMMENDATIONS
Optimal management of individuals with MMA and propionic acidemia includes careful dietary management and regular screening for known complications of the organic acidopathies [12,22,36 && ,56] . Table 1 catalogs the most common complications associated with propionic acidemia and MMA and the recommendations for screening and management. Metabolic 'strokes', frequently indicated by significant acute mental status changes or new or worsening abnormal movements, require immediate laboratory and imaging evaluation and reversal of catabolism [12, 17, 22, 34, [64] [65] [66] [195] [196] [197] . Once dextrose-containing intravenous fluids and treatment of the underlying precipitant are initiated, MRI and magnetic resonance spectroscopy may be performed to evaluate the location and extent of evolving injury [17,65,198 & ,199-201] . Movement disorders or spastic quadraparesis or paraparesis, potential sequelae of metabolic strokes, should be managed in collaboration with a neurologist and/or physiatrist to allow for optimal function and minimum disability. If spasticity or movement disorder worsens and limits the patient's ability to perform activities of daily living, referral to speech, physical, and/or occupational therapy should occur [202 ] . All individuals should be routinely screened with echocardiography and electrocardiogram (EKG) yearly, during admissions for illness (EKG), or with cardiac symptoms [12,36 && ]. Medications that prolong the QTc interval should be used with caution in organic acidopathy patients and avoided to the extent possible in patients with known cardiac disease. All patients who are hospitalized for metabolic decompensation or due to an invasive or surgical procedure should be placed on telemetry to monitor for life-threatening arrhythmias during these crises.
The significant ophthalmological effects of MMA and propionic acidemia require close collaboration with an ophthalmologist comfortable with managing the retinal and optic nerve degeneration associated with associated with these diseases [6, 7, 14, 35, 69, [205] [206] [207] [208] . Although effective ophthalmic therapies remain elusive, careful monitoring for vision loss and provision of support services are vital for maintaining patient function. As ophthalmological innovations occur for retinal and optic nerve disease, MMA and propionic acidemia patients with access to an ophthalmologist may benefit from trials with new devices and therapies.
MMA frequently, and propionic acidemia rarely, result in progressive, severe renal disease, often requiring transplant [8, [60] [61] [62] [63] [209] [210] [211] [212] [213] [214] [215] . Patients with MMA and propionic acidemia should be carefully screened with laboratory markers of renal function including BUN and creatinine, which are frequently near normal until late-stage disease, as well as calculated creatinine clearance or glomerular filtration rates, and cystatin C. Other markers of renal function, including erythropoietin and 1,25hydroxy vitamin D in the setting of appropriate vitamin D intake/supplementation may indicate additional investigation for worsening renal disease. Patients with indications of declining renal function require referral to a nephrologist for further evaluation and management, as dialysis and/or renal transplantation may become necessary, particularly in adolescents and adults with MMA. Nephrotoxic medications should also be avoided or limited in these patients.
Although the specific mechanisms associated with bone health in organic acidopathies remain incompletely investigated, patients with propionic acidemia and MMA are at significantly increased risk for osteopenia or osteoporosis that their agematched peers, with and without renal disease [22, 41] . DXA scan evaluation should be performed routinely starting at the age of 5 years, the earliest age for which height, race, and sex adjustment norms exist, and radiographic evaluation for fractures in patients presenting with pain should always be considered. Various disorders including vertebral fusion anomalies, vertebral compression and fractures, as well as generalized osteopenia have been observed. Therapeutic intervention should address morbidity associated with such low bone mineral density (BMD), and the use of bisphosphonates versus calcitriol to target antiresorption versus anabolic measures to support increased deposition is dependent on the individual patient's findings (BMD, bone age, parathyroid hormone, 1,25-OH and 25-OH vitamin D levels, and sex hormone production), and even bone biopsy should be considered for responsiveness to bisphosphonates prior to their initiation. If pathological fractures or significant osteopenia/osteoporosis are detected on screening, more robust monitoring for bone density and response to interventions are indicated. Currently, further studies are required to determine the role of medical food use, renal disease, or other contributing factors such as immobility or metabolic fragility in the development of low bone mineral density.
TRANSPLANT Some individuals have received liver transplants to treat propionic acidemia and liver, kidney, or combined liver-kidney to metabolically stabilize MMA and/or address the chronic renal failure associated with MMA disease [12,18 & ,24,59,195,200,216-226, 227 & ,228 & , 229 -238] . Liver transplantation has become an increasingly popular treatment choice for children with more severe or brittle disease, and some adults undergo isolated kidney transplant for MMA-related end-stage renal disease. For adolescents, however, combined liver and kidney transplant has also been employed in MMA. Liver transplantation does improve the metabolic stability of brittle organic acidopathy patients, and some sequelae may be mitigated, including cardiomyopathy. One center has claimed that liver transplantation is more cost-effective than dietary therapy alone [227 & ]. Not all sequelae of propionic acidemia and MMA may be prevented by liver transplantation; some liver-transplanted patients have developed metabolic stroke after transplant and others have had progressive vision loss due to optic atrophy as well [18 & ,230,231,235,238,239] . Further studies on the long-term outcomes of transplantation and changes to the natural history of disease are indicated.
CONCLUSION
For patients with propionic acidemia and MMA who survive their initial decompensation episode, significant morbidity remains a lifelong threat. Better therapies for these disorders remain elusive, but a critical mass of patients has now contributed to our understanding of the natural history of these diseases. Most importantly, recently proposed diagnostic and management guidelines have emerged from worldwide experts in these disorders and should improve management of these patients. Dietary management of the organic acidopathies should receive additional scrutiny in the near future with prospective, controlled studies to demonstrate the optimal circumstances for the use of medical foods and improvements in formulations of these foods to prevent iatrogenic morbidity. Better understanding of the pathophysiology of metabolic brain injury in the organic acidopathies must occur to permit further drug targeting for neuroprotection and recovery from metabolic insult. Finally, the use of orthotopic liver transplantation to improve metabolic stability in patients with organic acidopathies is burgeoning and will likely change the natural history of these disorders, yet we must ensure that our patients' families understand the limitations of this therapy, including ongoing risk to the central nervous system compartment following transplantation and the inherent risks of liver transplantation.
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